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Abstract
Transcranial magnetic stimulation (TMS) is a method that can be used in neurophysio‐
logical research of schizophrenia and in the treatment of some symptoms or syndromes
of this mental disorder. The most important indications for TMS (or repetitive TMS—
rTMS) are the negative symptoms of schizophrenia and auditory hallucinations. Other
less proven indications include cognitive deficit, especially working memory. This text
summarizes general knowledge about (r)TMS and its use in schizophrenia. According
to recent experiences, TMS is a very promising experimental and therapeutic method,
but it needs further research for its optimized use.
Keywords: transcranial magnetic stimulation, TMS, rTMS, schizophrenia, negative
symptoms, auditory hallucinations
1. Introduction
Transcranial magnetic stimulation (TMS) represents a relatively new method used in neuro‐
physiological research, in which it helps to measure various cortical phenomena, including
cortical inhibition, facilitation, and neuroplasticity. It is also used in the diagnosis and treatment
of certain neuropsychiatric disorders. This method is a neurostimulation (neuromodulation)
technique as is electroconvulsive therapy, vagal nerve stimulation, deep brain stimulation,
transcranial direct current stimulation, and magnetic seizure therapy. Some neurostimulation
techniques are invasive or semi‐invasive; others, including TMS, are noninvasive [1, 2].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. TMS principles, parameters and mechanism of action
The principle of the TMS method is based on Faraday’s law of electromagnetic induction,
formulated in 1831. This law states that around the primary coil through which a time‐varying
current is flowing, a changing magnetic field is created that is able to induce a secondary
current in conductors found within its reach. A patient’s brain may be one such conductor. The
secondary current induced is, according to Lenz’s law, in the direction opposing the primary
current. During TMS, an insulated metal coil is placed over the patient’s head that delivers a
changing electrical current producing a changing magnetic field perpendicular to the current
passing through the coil. Magnetic pulses may be administered individually (single‐pulse
TMS), or in pairs a few milliseconds apart (paired‐pulse TMS), or repeatedly in a sequence or
“train” lasting from seconds to minutes (repetitive transcranial magnetic stimulation or rTMS).
The first two options are used primarily for research and diagnostic purposes; rTMS is used
mainly in the treatment of certain neuropsychiatric disorders, including schizophrenia [1, 3].
Repetitive transcranial magnetic stimulation is defined by the number of pulses per second or
by frequency in Hertz (Hz). The frequency is categorized as “low‐frequency” (“slow”) rTMS
with 1 Hz or less and “high‐frequency” (“fast”) rTMS with more than 1 Hz (usually between
5 and 25 Hz). Another parameter of stimulation is its intensity expressed as the percentage of
the individual resting motor threshold (MT). The motor threshold is defined as the minimal
intensity of the stimulus able to produce muscle contraction in at least 5 of 10 successive trials
(usually in one of the small muscles of the hand, e.g., the abductor pollicis brevis) when the
stimulation is applied to the motor cortex. The most commonly used stimulation intensity
varies between 80% and 120% of the individual resting motor threshold. Other stimulation
parameters include the length of the train of pulses, the duration of the pause between them
(“intertrain”), the total number of pulses administered during one session, the total number
of individual sessions, the stimulation coil localization, the type of coil (the most commonly
used type in rTMS is the “figure‐of‐eight coil”; there are also oval coils, conical coils etc.; the
double cone coil is one of the most innovative types), and the coil’s position, and orientation
on the patient’s head. The most frequent stimulation site is the dorsolateral prefrontal cortex
(DLPFC). This stimulation site is usually defined as the location 5 cm rostral to the area of the
motor cortex, the stimulation of which determines the resting motor threshold. Another
method for the localization of the stimulation site uses the international system of EEG
electrode placement 10/20; the most precise localization method is performed by stereotactic
neuronavigation. An interesting modification of standard rTMS is pattern stimulation, with
theta burst stimulation (TBS) as the most important [1–3].
Although the specific effect of rTMS on neurotransmission is not entirely clear, it has been
proven repeatedly that high‐frequency rTMS (10 to 20 Hz) increases brain excitability, and low‐
frequency rTMS (1 Hz and lower) decreases it. It has also been found that high‐frequency rTMS
applied over the left prefrontal cortex (PFC) increases brain perfusion, and thus the metabolism
of this region, whereas low‐frequency rTMS has the opposite effect [4].
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3. TMS in neurophysiological research of schizophrenia
TMS with various single‐pulse protocols and paired‐pulse protocols is a useful tool for the
assessment of physiology of the human motor system, including cortical excitability, inhibitory
and excitatory mechanisms, conduction time, connectivity, and plasticity [5]. Moreover,
Camprodon and Pascual‐Leone [5] suppose that this tool has properties that we now need to
understand across affective, behavioral, and cognitive circuits, to establish solid circuit‐based
models of neuropsychiatric diseases with the potential to affect clinical practice.
One of the phenomena, studied with TMS, is cortical inhibition. Cortical inhibition (CI) can be
defined as a neurophysiological mechanism by which GABAergic interneurons influence the
activity of other neurons. Several studies have identified CI impairment in schizophrenia. CI
and CI impairment can be measured with a number of markers and protocols, including the
cortical silent period (CSP). CSP measurement consists of a suprathreshold TMS pulse over
the motor cortex paired with voluntary electromyographic activity, causing a cessation of
muscle movement. The duration of this movement cessation is a measure of CI. It is thought
that CSP measures GABAB inhibitory activity. Another CI marker is short‐interval cortical
inhibition (SICI). SICI measurement consists of a subthreshold conditioning TMS pulse
preceding a suprathreshold pulse by several ms (1–5 ms). The amplitude of the motor‐evoked
potential (MEP) is then measured; it should be reduced by 50–90%. This marker is thought to
measure GABAA‐mediated cortical inhibition [6–13]. Recent studies show that CI impairment
can be improved with antipsychotics, especially clozapine, but also with quetiapine and
risperidone [13–15]. Kaster et al. [13] suggested that the potentiation of GABAB may be a novel
neurotransmitter mechanism that is involved in the pathophysiology and the treatment of
schizophrenia. Another recent study found inhibitory deficits directly in the prefrontal cortex
specific for schizophrenia using a combination of TMS and electroencephalography (EEG) [9].
Camprodon and Pascual‐Leone [5] suppose that this multimodal combination of TMS and
neuroimaging methods (EEG, magnetic resonance imaging, or positron emission tomography)
can achieve TMS full potential—to measure the neurobiological effects of TMS even beyond
the motor cortex.
4. Clinical application of TMS in schizophrenia
The most important use of TMS (or rTMS) is in the treatment of specific symptoms or syn‐
dromes of schizophrenia, especially negative symptoms and auditory hallucinations. Other
less proven indications in schizophrenia include cognitive deficit, catatonic symptoms,
obsessive‐compulsive symptoms, and comorbid nicotine abuse (through the decrease of
craving).
4.1. Negative symptoms
There is a consensus that the negative symptoms of schizophrenia include symptoms of
affective flattening, alogia, avolition, social withdrawal, and anhedonia. The symptoms of
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inattention, poverty of content of speech, and inappropriate affect are also often assigned in
measuring scales mainly due to the clinical evaluation of the overall disorganization seen in
patients with schizophrenia [16].
Severity of negative symptoms in schizophrenia is usually linked with worse functional
outcomes, including specific relationships with impaired occupational functioning, household
integration, social functioning, engagement in recreational activities, and quality of life [16—18].
Negative symptoms are often associated with hypofrontality and with a lack of dopamine in
the prefrontal cortex [19, 20].
4.1.1. Effect of rTMS in the prefrontal cortex
Some authors have found that high‐frequency rTMS could increase cortical excitability and
the metabolic activity of targeted neurons [21, 22]. Prefrontal rTMS also modulates dopamine
release in the dorsal striatum and in the nucleus accumbens in Wistar rats [23]. High‐frequency
rTMS of the DLPFC induces the release of dopamine in the ipsilateral nucleus caudatus in
healthy volunteers, and it causes downregulation of the 5‐HT2 receptors in the frontal cortex
[24, 25].
The change of the expression of glutamic acid decarboxylase, which is the synthetic enzyme
of the precursor of GABA, could be also modified by rTMS. This finding may be important
because the severity of negative symptoms has been found to be inversely related to benzo‐
diazepine receptor binding in the medial frontal region [26].
These findings have led to the hypothesis that high‐frequency rTMS applied at the prefrontal
cortex may be an effective treatment of negative symptoms in schizophrenia, and many studies
were published on this topic.
4.1.2. Current results of rTMS in the treatment of negative symptoms
We summarize in this text the results from three meta‐analyses and from recent articles that
are not a part of the last meta‐analysis by Shi et al. [27].
The first meta‐analysis reviewed eight double‐blind studies and found that rTMS had a mild
to moderate (d = 0.58) effect on alleviating the negative symptoms of schizophrenia [28]. The
second meta‐analysis evaluated nine double‐blind studies with more than 200 enrolled
patients [29]. When studies with any high‐frequency stimulation of the left PFC were evalu‐
ated, the effect size of the treatment was low (d = 0.43); when the analysis included only studies
with a 10 Hz frequency, the effect size of the treatment was intermediate (d = 0.63) [29]. The
results of the third, most recent, meta‐analysis suggest that rTMS is an effective treatment
option for negative symptoms in schizophrenia. This meta‐analysis included 16 studies. The
moderators of rTMS on negative symptoms included duration of illness, stimulation frequen‐
cy, stimulation intensity, and the type of outcome measures used (the effect size of rTMS on
negative symptoms in sham‐controlled trials was 0.80 as measured by the Scale for the
Assessment of Negative Symptoms—SANS and 0.41 as measured by the Positive and Negative
Syndrome Scale—PANSS) [27].
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The authors of the third meta‐analysis formulated some recommendations for the treatment
of negative symptoms by rTMS based on the available results, which show that long‐term
stimulation (3 weeks or more) has a better effect than short‐term stimulation. The best effect
was with 10 Hz rTMS and 110% of individual MT. The number of pulses is also important—
the effect is greater when the patient receives a higher number of pulses [27].
A recent study by Wobrock et al. included a sufficiently large sample (175 patients), but no
statistically significant effect of rTMS was found in the improvement of negative symptoms in
the active group compared with the sham group. The stimulation protocol was 15 sessions of
10 Hz stimulation of the left DLPFC, 110% MT, 5 s train and 30 s intertrain, and 15,000 pulses
in the whole study. However, less‐precise method was used for targeting the left DLPFC (the
international system of EEG electrode placement 10/20, F3 electrode), and patients received a
relatively small number of pulses, although the last meta‐analysis indicated that a higher
number of pulses have a better effect [30].
In another double‐blind study, 117 patients with negative symptoms were randomized to a 20‐
day course of either active rTMS applied to the left DLPFC (it was targeted to 5 cm anterior to
the point where maximum stimulation of the abductor pollicis brevis muscle was observed)
or sham rTMS. The stimulation protocol was 10 Hz frequency, 4 s train and 56 s intertrain,
20 min each day, 80% MT, and 800 pulses per day. They reported that treatment with high‐
frequency rTMS for 6 weeks significantly improved negative symptoms in the active stimula‐
tion group as compared to the sham group. The decrease in negative symptoms persisted to
the 6‐month follow‐up assessment [31].
Dlabac‐de Lange et al. evaluated the effect of bilateral rTMS of DLPFC in schizophrenia
patients with negative symptoms. The Tower of London (ToL) task during fMRI was used to
measure the brain function of the DLPFC. The stimulation protocol was 10 Hz frequency, 15
sessions (divided into 3 weeks), 10 s train and 50 s intertrain, and 90% MT. Patients received
20 trains in one stimulation session. The brain activity in the right DLPFC and in the right
medial frontal gyrus showed an increase in the active stimulation group after the stimulation,
and the left posterior cingulate showed a decrease in brain activity after rTMS treatment of the
DLPFC. No significant differences were found in task performance between the sham group
and the active group after the treatment with rTMS. A significant difference was found in SANS
but not in PANSS. The limits of the study can be seen in the localization of the DLPFC (targeted
by F3 and F4 location from the EEG 10/20 system), in the small sample size (total of 24 patients)
and in its heterogeneity, as there were significant differences between the active and sham
groups at the beginning of the study [32].
4.1.3. New paradigms of rTMS in the treatment of negative symptoms
The authors of a recent study compared 96 patients who received 10 and 20 Hz, theta burst
stimulation (TBS) and sham stimulation. The 10 Hz stimulation was only 80% MT at the be‐
ginning, and the intensity was gradually increased to 110% MT. Patients received 30 trains in
one stimulation day, one stimulation interval was 5 s of the train and 30 s of the intertrain.
The stimulation was divided into four weeks (20 stimulation sessions). The 20 Hz stimula‐
tion had the same stimulation parameters as the 10 Hz stimulation. In TBS, the basic train
Transcranial Magnetic Stimulation in Schizophrenia
http://dx.doi.org/10.5772/65631
139
had a frequency of 5 Hz, and the stimulation was given every 200 ms. Three single pulses
(50 Hz) were embedded within each 5 Hz pulse, on 80% MT, and each session had 2400
pulses. The TBS group had significantly larger reductions in SANS and PANSS negative
subscale scores than the 10 Hz group and the 20 Hz group, but there were no significant
differences in the two scales between the 10 and 20 Hz groups. There was a reduction in the
scores in the mentioned scales in all groups with active stimulation compared with the sham
group stimulation [33].
The cerebellum and cortico‐thalamic‐cerebellar circuit have also been included in the patho‐
physiology of schizophrenia. In patients with schizophrenia, some cerebellar dysfunctions
were found, such as neurological soft signs, impaired eyeblink conditioning, procedural
learning deficits, dyscoordination, abnormal posture, and poor cognitive performance. Resting
state gamma activity is supposed to be a biomarker related to functional brain connectivity.
One study tried to investigate the effect of cerebellar rTMS on resting state gamma activity.
The efficacy of cerebellar rTMS was tested in 11 recent‐onset schizophrenia patients who
received 10 sessions of high‐frequency rTMS to the midline cerebellum over a 2‐week period.
A significant decrease in negative symptoms and depression scores was observed after the
rTMS treatment. Gamma spectral power in left frontal and temporal segments was reduced
significantly after this treatment. In light of these preliminary results, cerebellar rTMS could
be a useful innovation for the treatment of negative and affective symptoms in schizophrenia,
but this has to be confirmed in further studies [34].
4.1.4. Negative symptoms and rTMS—summary
Recent guidelines state that high‐frequency rTMS of the left DLPFC has a probable effect in
the treatment of negative symptoms of schizophrenia (Level B evidence) [35].
A number of double‐blind studies also proved a statistically significant decrease in the
intensity of negative schizophrenia symptoms when current antipsychotic treatment was
augmented with rTMS; the actual clinical significance of this procedure is disputed [4].
Another issue is represented by antipsychotic and other medication used in the treatment of
patients with schizophrenia. According to some studies, this medication could negatively
influence the activation induced by rTMS [36, 37].
rTMS represents a promising direction in the treatment of negative symptoms in schizophre‐
nia, but it is necessary to improve current stimulation protocols (to use different frequencies
in different areas, to investigate the effects of intensive stimulation protocols, and to investigate
new targets such as the cerebellum).
4.2. Auditory hallucinations
Auditory verbal hallucinations (AVH), perceptions of voices in the absence of external stimuli,
are a fundamental feature of mental illness and one of the characteristic symptoms of schizo‐
phrenia with high clinical importance [38]. AVH are reported by 50–70% of patients with
schizophrenia, and in about 25–30% of patients, AVH are resistant to antipsychotic medication
[39]. rTMS could be an additional therapeutic tool for AVH in schizophrenia [40].
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4.2.1. Effect of rTMS on auditory hallucinations
The positive impact of rTMS on AVH can be seen in the inhibition of increased activity in the
left temporoparietal cortex (TPC) (Broadmann area 40). This increased activity is repeatedly
proven during hallucinations using brain imaging methods. This area is supposed to be
involved in the perception of speech. The repeated stimulation of this area with a frequency
of 1 Hz (low‐frequency rTMS) induces a long‐lasting decrease in the frequency and severity
of medication‐resistant AVH [41].
4.2.2. Current results of clinical studies and meta-analyses
The first study that applied rTMS as a therapeutic instrument for AVH was performed by
Hoffman et al. in 1999. They postulated that low‐frequency rTMS (1 Hz frequency) delivered
to the left TPC would curtail auditory hallucinations by reducing the excitability of distributed
neurocircuitry [39]. Since then several studies have been performed; some studies with positive
results and others with negative results. All these studies were included in several meta‐
analyses.
The authors of the first meta‐analysis observed a significant mean weighted effect size for rTMS
versus sham stimulation, across 10 studies involving 212 patients (d = 0.76). The main outcome
measure was the reduction in hallucinations as measured with appropriate psychometric
rating scales. A typical hallucination rating scale is the Auditory Hallucinations Rating Scale
(AHRS), which is a seven‐item scale measuring frequency, reality, perceived loudness, number
of different speaking voices, length of hallucinations (single words, phrases, sentences, or
extended discourse), attentional salience (the degree to which hallucinations captured the
attention of the patient), and distress level. When studies reported on multiple brain areas that
were targeted with rTMS, only the left TPC was included. When only studies were included
that used continuous stimulation (nine studies), the mean effect size increased to d = 0.88. To
investigate whether the number of stimulation session would be an important variable, they
compared studies with fewer than five stimulation sessions (four studies) to those with more
than five stimulation sessions (six studies); there was no significant improvement. Two studies
that included PANSS reported that rTMS had no significant effect on the PANSS positive
subscale. Thus, the observed effect was specific to auditory hallucinations. There was no
significant effect of rTMS on a composite index of general psychotic symptoms. The results
provide support for the efficacy of the treatment in reducing the severity of AVH [42].
The second meta‐analysis included ten studies with 232 patients. All these studies used low‐
frequency rTMS of the left TPC on patients with schizophrenia and treated and measured
medication‐resistant AVH. They extracted outcomes from several scales for assessing AVH:
Hallucination Change Scale (HCS), Auditory Hallucinations Rating Scale (AHRS), Severity of
Auditory Hallucinations (SAH scale), Psychotic Symptom Rating scale—Auditory Hallucina‐
tions Subscale (PSYRATS‐AH), and Positive and Negative Syndrome Scale—Auditory
Hallucinations Item (PANSS‐AH). The HCS seems more sensitive to rTMS effects on AVH,
while most studies using AHRS reported negative results. The authors observed significant
effect size (Hedges’ g = 0.514) [43].
Transcranial Magnetic Stimulation in Schizophrenia
http://dx.doi.org/10.5772/65631
141
The third meta‐analysis was performed by Freitas et al. [28]. The authors specifically analyzed
the effect on auditory hallucinations in seven sham‐controlled studies and found a large and
significant effect size for the sham‐controlled studies (1.04; p = 0.002). They observed the need
for individual assessment of the functional anatomy of hallucinations, using hallucination‐
activation maps obtained either by PET or fMRI, and stereotaxically determined the stimula‐
tion site following individual fMRI detection of inner speech regions instead of less
sophisticated approach including coil position using the international 10/20 EEG electrode
system in TP3 site, which might enhance TMS efficacy [43]. A critical finding in a study by
Hoffman et al. concerned the discrepancy between the fMRI‐guided TPC sites used in their
trial and the standard TP3 which had little to no overlap [44]. Moreover, in a study by Sommer
et al., five of the seven patients undergoing functional guided rTMS had predominant right‐
sided hallucinatory activity and were therefore stimulated over the right TPC [28, 45].
Another three meta‐analyses were published by Slotema et al. [41, 46, 47]. According to the
first one, with seven randomized controlled trials and 189 patients included, rTMS was
superior to sham treatment, with a mean weighted effect size of 0.54 [46]. The second meta‐
analysis included 17 studies. The mean weighted effect size of rTMS directed at the left
temporoparietal area was 0.44. But the effect of rTMS was no longer significant at one month
of follow‐up care (according to five studies with a follow‐up assessment of at least one month)
[47]. The most recent meta‐analysis by Slotema included 19 studies with a total number of 548
patients. The mean weighted effect size for the treatment of auditory hallucinations was 0.44.
No significant mean weighted effect size was found for the severity of psychosis. For patients
with medication‐resistant auditory hallucinations, the mean weighted effect size was 0.45.
Repetitive transcranial magnetic stimulation applied at the left temporo‐parietal area with a
frequency of 1 Hz yielded a moderate mean weighted effect size of 0.63, indicating the
superiority of this paradigm. Various other paradigms failed to show superior effects. rTMS
applied at the right temporo‐parietal area was not superior to sham treatment. The authors
concluded that rTMS, especially when applied at the left temporo‐parietal area with a
frequency of 1 Hz, is effective for the treatment of auditory hallucinations, including for
patients with medication‐resistant hallucinations [41]. The limitation of all rTMS studies is the
placebo, because of the difficulty of reproducing the noise and the scalp sensation (including
superficial muscle contractions) of the active treatment. The initial method of producing a
placebo effect was to tilt the coil at 45° or 90°. However, this method clearly unmasks it to
patients who were previously treated with rTMS or for those in a crossover design. The more
recent methods involve using a completely similar sham coil. Another significant limitation of
these studies is the concomitant pharmacotherapy in all subjects. Several pharmacological
treatments may interfere with treatment response, by modifying cortical excitability, by
preventing the transsynaptic transmission of rTMS, or by interfering with the cerebral
plasticity effects induced by rTMS [43].
4.2.3. Auditory hallucinations and rTMS—summary
The results of all of these meta‐analyses show that 1 Hz rTMS applied at the left temporo‐
parietal area is effective in the treatment of auditory hallucinations (even in treatment‐resistant
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patients), but the effect is of a relatively short duration (shorter than in patients with depressive
disorder). In the trials covered in the meta‐analysis by Slotema et al. [47], the effect of rTMS
on AVH was no longer significant at the one‐month follow‐up visit. This short duration of the
effect of rTMS is a matter of concern. A daily treatment of 2–4 weeks with a small treatment
effect combined with a short duration may call into question its utility as a meaningful
treatment for patients troubled by persistent symptoms [47]. The treatment of other positive
symptoms with rTMS is ineffective. Recent guidelines state that low‐frequency rTMS of the
left TPC has a possible effect in the treatment of auditory hallucinations (Level C evidence);
for other paradigms (high‐frequency rTMS or continuous theta burst stimulation—cTBS),
there are no recommendations [35].
4.3. Other indications
The treatment of other symptoms, syndromes, and comorbid conditions in patients with
schizophrenia is less proven. Some studies focused on the cognitive effects of rTMS in
schizophrenia. Their results were heterogeneous. A meta‐analysis included four studies of
high‐frequency rTMS at the DLPFC and its effect on working memory. The authors concluded
that rTMS significantly improved all measures of working memory performance [48]. But a
recent study failed to prove a superior effect of rTMS over sham stimulation in the improve‐
ment of various cognitive domains in 156 schizophrenia patients with predominant negative
symptoms [49]. Recent guidelines state no recommendations for the treatment of cognitive
deficit in schizophrenia [35].
Three case studies described rTMS in the treatment of catatonic symptoms in patients with
schizophrenia—the improvement in two cases was rapid and sufficient; the last case was
negative [50].
A similar situation was seen in the treatment of obsessive‐compulsive symptoms associated
with schizophrenia. Two case studies with positive results were published, but the effect was
only transient, and a recent pilot study had negative results [51, 52].
TMS offers an interesting option for the treatment of comorbid misuse of alcohol, nicotine, and
other psychotropic substances. Two studies proved the effect of high‐frequency rTMS at the
left DLPFC on the reduction in cigarette consumption in patients with schizophrenia [53, 54].
TMS could also influence other less specific symptoms which are presents in schizophrenia as
well as in other mental disorders, such as attention deficit or impulsiveness.
5. Future directions
It is possible to distinguish between two categories of factors associated with the efficacy of
rTMS in schizophrenia: (1) clinical factors and (2) factors associated with rTMS, especially
stimulation parameters.
Clinical factors include heterogeneity of symptoms of schizophrenia treated with rTMS,
especially negative symptoms. Prikryl et al. analyzed negative symptoms influenced with
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rTMS using five domains of SANS (affective flattening/blunting, alogia, avolition/apathy,
anhedonia, and impaired attention). The stimulation improved all domains, except for alogia
[4]. To improve the results with rTMS, the definition and the prediction of responders are
needed. This could be achieved using markers of impaired cortical inhibition and neuroplas‐
ticity—especially when TMS (with the potential to measure cortical inhibition and its changes)
and EEG or other neuroimaging methods (MRI, fMRI, SPECT, PET) are combined. Tikka et al.
described significant correlation between the reduction in negative and depressive symptoms
in patients with schizophrenia and the reduction in gamma spectral power in left frontal and
temporal segments after cerebellar rTMS. The authors suggest resting state gamma spectral
power in frontal and temporal regions for a biomarker of treatment response [55]. Homan et
al. described that responders were robustly differentiated from nonresponders to rTMS by the
higher regional blood flow in the left superior temporal gyrus before treatment for AVH. The
authors conclude that resting perfusion measurement before treatment might be a clinically
relevant way to identify possible responders and nonresponders to rTMS [56].
The optimization of stimulation parameters is another important issue. New stimulation
targets (for example, the cerebellum or anterior cingulate), better and more precise methods
of stimulation coil placement (stereotactic navigation), new coil types (double cone coil, maybe
H‐coils for deep TMS), stimulation frequency (individual frequency), intensity, number of
pulses (higher number of pulses), and the number of stimulation sessions (intensive stimula‐
tion) are also subjects of current research. This research can provide data for new and inno‐
vative stimulation paradigms, which are needed for a more robust clinical effect of TMS in
schizophrenia.
6. Conclusion
TMS is a very promising research and therapeutic method for patients with schizophrenia. It
is a useful tool for researching cortical inhibition and neuroplasticity. The most important
application of TMS (or rTMS) is in the treatment of some symptoms or syndromes, especially
negative symptoms (high‐frequency rTMS at the left DLPFC) and auditory hallucinations
(low‐frequency rTMS at the left TPC), and maybe even cognitive deficit. The results of clinical
studies are promising, but further research is needed to optimize the treatment results.
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